{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:32:34Z","timestamp":1789471954119,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["215S008"],"award-info":[{"award-number":["215S008"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["R01CA244344"],"award-info":[{"award-number":["R01CA244344"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijbiomac.2026.151860","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:11:47Z","timestamp":1775455907000},"page":"151860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Computational discovery and preclinical validation of a novel nanodrug eEF2 kinase inhibitor for suppression of tumor growth in triple-negative breast cancer by induction of ferroptosis and apoptosis"],"prefix":"10.1016","volume":"360","author":[{"given":"Ferah Comert","family":"Onder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nermin","family":"Kahraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Siyah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdar","family":"Durda\u011f\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen Bellur","family":"Atici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Atalay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayra","family":"Dilmac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumeysa","family":"Ozyurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goknur","family":"Kara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogun","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Fokt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Priebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Guzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Ozpolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2026.151860_bb0005","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1634\/theoncologist.2016-0067","article-title":"Biology and management of patients with triple-negative breast cancer","volume":"21","author":"Sharma","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.amjsurg.2012.10.025","article-title":"The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer","volume":"206","author":"Spanheimer","year":"2013","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0015","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/COC.0b013e3181b8afcf","article-title":"Triple-negative breast cancer: a short review","volume":"33","author":"Elias","year":"2010","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0020","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0025","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0030","doi-asserted-by":"crossref","DOI":"10.4081\/oncol.2021.497","article-title":"Immunotherapy using PD-1\/PDL-1 inhibitors in metastatic triple-negative breast cancer: a systematic review","volume":"15","author":"Tavares","year":"2021","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0035","article-title":"Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jbior.2014.04.003","article-title":"Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles","volume":"55","author":"Kenney","year":"2014","journal-title":"Advances in Biological Regulation"},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0045","doi-asserted-by":"crossref","first-page":"11641","DOI":"10.18632\/oncotarget.14264","article-title":"MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase","volume":"8","author":"Bayraktar","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0050","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2217\/nnm-2019-0132","article-title":"EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer","volume":"14","author":"Asik","year":"2019","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0055","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.15252\/emmm.201404402","article-title":"Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K","volume":"6","author":"Liu","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0041171","article-title":"Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer","volume":"7","author":"Tekedereli","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-025-07803-w","article-title":"eEF2K is a poor prognostic factor and novel molecular target in pancreatic cancer: regulating tumor growth and progression via the tumor microenvironment","volume":"16","author":"Karakas","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0070","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1111\/jcmm.12361","article-title":"Elongation factor-2 kinase regulates TG 2\/\u03b21 integrin\/Src\/u PAR pathway and epithelial\u2013mesenchymal transition mediating pancreatic cancer cells invasion","volume":"18","author":"Ashour","year":"2014","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.109938","article-title":"Targeting eukaryotic elongation factor-2 kinase sup-presses the growth and peritoneal metastasis of ovarian cancer","volume":"81","author":"Erdogan","year":"2021","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lungcan.2018.07.027","article-title":"Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and pro-motes proliferation, invasion and tumor growth of lung cancer","volume":"124","author":"Bircan","year":"2018","journal-title":"Lung Cancer"},{"issue":"14","key":"10.1016\/j.ijbiomac.2026.151860_bb0085","doi-asserted-by":"crossref","first-page":"6792","DOI":"10.3390\/ijms26146792","article-title":"Inhibition of FOXM1 leads to suppression of cell proliferation, migration, and invasion through AXL\/eEF2 kinase signaling and induces apoptosis and Ferroptosis in GBM cells","volume":"26","author":"Biltekin","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/334170a0","volume":"334","author":"Ryazanov","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0014-5793(89)81452-8","article-title":"Mechanism of elongation factor 2 (EF-2) inactivation upon phosphorylation. Phosphorylated EF-2 is unable to catalyze translocation","volume":"251","author":"Ryazanov","year":"1989","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0100","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1432-1033.1990.tb19169.x","article-title":"Functional properties of phosphorylated elongation factor 2","volume":"191","author":"Carlberg","year":"1990","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/cbf.1740","article-title":"Eukaryotic elongation factor-2 (eEF2): its regulation and peptide chain elongation","volume":"29","author":"Kaul","year":"2011","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0110","doi-asserted-by":"crossref","first-page":"30337","DOI":"10.1074\/jbc.274.43.30337","article-title":"Signal transduction pathways that regulate eukaryotic protein synthesis","volume":"274","author":"Rhoads","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0115","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00109-020-01917-8","article-title":"Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target","volume":"98","author":"Karakas","year":"2020","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0125","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1039\/D2MD00105E","article-title":"Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy","volume":"13","author":"Comert Onder","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0130","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0076-6879(97)77022-8","article-title":"VERIFY3D: assessment of protein models with three-dimensional profiles","volume":"277","author":"Eisenberg","year":"1997","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1107\/S0021889892009944","article-title":"PROCHECK: a program to check the stereochemical quality of protein structures","volume":"26","author":"Laskowski","year":"1993","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0140","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1021\/acsptsci.1c00030","article-title":"Target-driven design of a coumarinyl chalcone scaffold based novel EF2 kinase (EF2K) inhibitor suppresses breast cancer growth","volume":"4","author":"Comert Onder","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0145","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jcc.20222","article-title":"Importance of accurate charges in molecular docking: quantum mechanical\/molecular mechanical (QM\/MM) approach","volume":"26","author":"Cho","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0150","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0155","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0160","series-title":"SC'06: Proceedings of the 2006 ACM\/IEEE Conference on Supercomputing","first-page":"43","article-title":"Scalable algorithms for molecular dynamics simulations on commodity clusters","volume":"vol. 11","author":"Bowers","year":"2006"},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0165","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1063\/1.449071","article-title":"The nose\u2013hoover thermostat","volume":"83","author":"Evans","year":"1985","journal-title":"J. Chem. Phys."},{"issue":"4177","key":"10.1016\/j.ijbiomac.2026.151860_bb0170","first-page":"10","article-title":"Constant pressure molecular dynamics algorithms","volume":"101","author":"Martyna","year":"1994","journal-title":"J. Chem. Phys."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151860_bb0175","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/prot.10613","article-title":"A hierarchical approach to all-atom protein loop prediction","volume":"55","author":"Jacobson","year":"2004","journal-title":"Proteins Struct. Funct. Genet."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0180","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10549-018-4847-2","article-title":"Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer","volume":"171","author":"Kabil","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0185","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.omtn.2021.01.016","article-title":"ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer","volume":"23","author":"Gorur","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0190","doi-asserted-by":"crossref","first-page":"16619","DOI":"10.18632\/oncotarget.7672","article-title":"FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells","volume":"7","author":"Hamurcu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.mex.2023.102488","article-title":"Synthesis and pharmacological properties of coumarin-chalcones","volume":"11","author":"Bensalah","year":"2023","journal-title":"MethodsX"},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0200","series-title":"EF2 Kinase Enzyme Inhibiting Novel Compounds","author":"Ay","year":"2019"},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0205","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejmech.2013.07.014","article-title":"Polyoxygenated cinnamoylcoumarins as conformationally constrained analogs of cytotoxic di- arylpentanoids: synthesis and biological activity","volume":"68","author":"Molaverdi","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0210","doi-asserted-by":"crossref","first-page":"43951","DOI":"10.1074\/jbc.M111.301291","article-title":"1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor","volume":"286","author":"Chen","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0215","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/S0968-0896(02)00160-8","article-title":"TX-1123: an antitumor 2-Hydroxyarylidene-4-cyclopentene-1,3-Dione as a protein tyrosine kinase inhibitor having low mitochondrial toxicity","volume":"10","author":"Hori","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0220","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1021\/acs.jcim.9b01083","article-title":"Design, synthesis, and molecular modeling studies of novel Coumarin Carboxamide derivatives as eEF-2K inhibitors","volume":"60","author":"Comert Onder","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0225","article-title":"Novel inhibitors of eukaryotic elongation factor 2 kinase: in silico, synthesis, and in vitro studies","volume":"116","author":"Comert Onder","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0230","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1078-0432.CCR-14-3304","article-title":"Relationship between complete pathologic response to neoadjuvant chemotherapy and survival in triple-negative breast Cancer","volume":"22","author":"Hatzis","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0235","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/sj.clpt.6100449","article-title":"Advances in the treatment of breast cancer","volume":"83","author":"Moulder","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0240","article-title":"Early-stage triple-negative breast cancer journey: beginning, end, and everything in between","volume":"43e","author":"Han","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"W1","key":"10.1016\/j.ijbiomac.2026.151860_bb0245","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.727863","article-title":"Insights into the pathologic roles and regulation of eukaryotic elongation Factor-2 kinase","volume":"8","author":"Ballard","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0255","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.3390\/ijms22052408","article-title":"Progress in the development of eukaryotic elongation factor 2 kinase (eEF2K) natural product and synthetic small molecule inhibitors for Cancer chemotherapy","volume":"22","author":"Zhang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0260","doi-asserted-by":"crossref","first-page":"8870","DOI":"10.1021\/acs.jmedchem.0c02218","article-title":"Inhibiting eukaryotic elongation factor 2 kinase: an up-date on pharmacological small-molecule compounds in Cancer","volume":"64","author":"Zhu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0265","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1016\/j.bmc.2014.06.050","article-title":"Synthesis and biological evaluation of pyrido[2,3-d]pyrimidine-2,4-dione derivatives as eEF-2K inhibitors","volume":"22","author":"Edupuganti","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0270","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/cbic.201402321","article-title":"Reversible covalent inhibition of eEF-2K by carbonitriles","volume":"15","author":"Devkota","year":"2014","journal-title":"Chembiochem"},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0275","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.2174\/1389557521666210405160323","article-title":"Anticancer potential of Coumarin and its derivatives","volume":"21","author":"Bhattarai","year":"2021","journal-title":"Mini Rev. Med. Chem."},{"issue":"Pt 1","key":"10.1016\/j.ijbiomac.2026.151860_bb0280","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/bj3510095","article-title":"Specificity and mechanism of action of some commonly used protein kinase inhibitors","volume":"351","author":"Davies","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijbiomac.2026.151860_bb0285","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2020.02.015","article-title":"Eukaryotic elongation factor 2 kinase a pharmacological target to regulate protein translation dysfunction in neurological diseases","volume":"445","author":"Beretta","year":"2020","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151860_bb0290","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/jnc.15541","article-title":"Roles of eukaryotic elongation factor 2 kinase (eEF2K) in neuronal plasticity, cognition, and Alzheimer disease","volume":"166","author":"Ma","year":"2023","journal-title":"J. Neurochem."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026017861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026017861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:48:54Z","timestamp":1778716134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026017861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":58,"alternative-id":["S0141813026017861"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151860","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Computational discovery and preclinical validation of a novel nanodrug eEF2 kinase inhibitor for suppression of tumor growth in triple-negative breast cancer by induction of ferroptosis and apoptosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151860","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151860"}}